Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer (NCT02393625)

🧪 Interventions in This Study

• Ceritinib (LDK378) (DRUG)
• Nivolumab (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (12 Sites)

• Mayo Clinic - Arizona — Scottsdale, Arizona
• Massachusetts General Hospital — Boston, Massachusetts
• Massachusetts General Hospital Thoracic Oncolgoy — Boston, Massachusetts
• Fox Chase Cancer Center — Philadelphia, Pennsylvania
• Novartis Investigative Site — Heidelberg, Victoria
• Novartis Investigative Site — Leuven, Vlaams Brabant
• Novartis Investigative Site — Toronto, Ontario
• Novartis Investigative Site — Hong Kong,
• Novartis Investigative Site — Milan, MI
• Novartis Investigative Site — Modena, MO
• Novartis Investigative Site — Singapore,
• Novartis Investigative Site — Barcelona,

📞 Contact the Study Coordinator

Phone: (800) 664-4580

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in ALK-positive NSCLC

• A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC — San Francisco, California

Explore by condition: All ALK-positive NSCLC clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.